AG
YMAB

Algert Global’s Y-mAbs Therapeutics YMAB Stock Holding History

Algert Global’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-26,670
Closed -$145K – 1280
2023
Q3 		$145K Sell
26,670
-17,800
-40% -$104K 0.01% 999
2023
Q2 		$302K Buy
44,470
+18,650
+72% +$140K 0.01% 906
2023
Q1 		$129K Hold
25,820
– – 0.01% 1070
2022
Q4 		$126K Buy
25,820
+8,338
+48% +$60.6K 0.01% 1049
2022
Q3 		$252K Buy
17,482
+2,918
+20% +$48.3K 0.02% 989
2022
Q2 		$220K Buy
14,564
+4,050
+39% +$47.3K 0.02% 1000
2022
Q1 		$125K Buy
+10,514
New +$108K 0.01% 1089

Other funds holding YMAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Algert Global's YMAB Position: Q4 2023 in Review

Algert Global sold out of Y-mAbs Therapeutics (YMAB) in Q4 2023, closing a stake of 26,670 shares — an estimated $145K sold.

Algert Global first reported a position in YMAB in Q1 2022 and held it in 7 quarters. The position peaked at $302K in Q2 2023. 94 funds tracked by Wall St. Rank hold YMAB as of Q4 2023.

  • Algert Global reported no remaining Y-mAbs Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Algert Global sold 26,670 Y-mAbs Therapeutics shares in Q4 2023, an estimated $145K.
  • Algert Global first reported a position in Y-mAbs Therapeutics in Q1 2022 and held it in 7 quarters.
  • Algert Global's Y-mAbs Therapeutics position peaked at $302K in Q2 2023.
  • 94 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q4 2023.

Based on Algert Global's 13F filing for Q4 2023, filed 14 Feb 2024.